Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using the LightCycler PCR assay, the EGFR L858R mutation status might correlate with gender, pathologic subtypes, and gefitinib sensitivity of lung cancers.
|
15837743 |
2005 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR mutations (CTG-->CGG; L858R) were found from 14 of 95 lung cancer patients.
|
16003726 |
2006 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.
|
16705038 |
2006 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The EGFR mutation status, especially L858R mutation might be correlated with the clinico-pathological features related to good response to gefitinib, such as gender, smoking history, and pathological subtypes of Japanese lung cancers.
|
16890322 |
2006 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
We aim to develop a digital PCR-based method for the quantitative detection of the two common epidermal growth factor receptor (EGFR) mutations (in-frame deletion at exon 19 and L858R at exon 21) in the plasma and tumor tissues of patients suffering from non-small cell lung cancers.
|
19276259 |
2009 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.
|
20574956 |
2010 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The loop-hybrid mobility shift assay (LH-MSA) was previously developed for the rapid detection of the EGFR mutation L858R for predicting clinical responses to gefitinib in lung cancer.
|
21741959 |
2011 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genetic analysis suggested that the specific EGFR mutation L858R in exon 21 might be the main factor contributing to lung carcinogenesis in multiple lung cancers.
|
22733594 |
2012 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Approximately 50% of lung cancer patients with epidermal growth factor receptor (EGFR)-mutations (deletion in exon 19 or L858R) who develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) reportedly carry a secondary EGFR T790M mutation.
|
22899358 |
2012 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
A total of 50 lung cancer patients' tumor tissues were analyzed, and two frequent mutations associated with therapeutic efficiency of lung cancer were identified, including deletion of exon 19 (8/50) and L858R point mutation in exon 21 (12/50).
|
22901298 |
2012 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In preclinical studies, afatinib not only inhibited the growth of models with common activating EGFR mutations, but was also active in lung cancer models harboring wild-type EGFR or the EGFR L858R/T790M double mutant.
|
23664448 |
2013 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L858R + T790M resistance mutation.
|
23937717 |
2013 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
We identified a reference range for EGFR L858R and exon 19 deletions in specimens from KRAS-mutant lung cancer, allowing identification of candidate thresholds with high sensitivity and 100% specificity.
|
24429876 |
2014 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
|
24453288 |
2014 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Next, we examined the role of RhoB in lung cancer progression in transgenic mice that express inducible EGFR(L858R) crossed with Rhob null mice.
|
25320360 |
2014 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
To further access a physiological role of MALT1-dependent NF-κB activation in EGFR-driven tumor progression, we generated triple-transgenic mouse model (tetO-EGFR(L858R); CCSP-rtTA; Malt1(-/-)), in which mutant EGFR-driven lung cancer was developed in the absence of MALT1 expression.
|
25982276 |
2016 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Ectopic expression of EGFR-L858R in lung cancer cells acted through activation of ERK signaling pathways to induce the expression of CXCR4.
|
26338423 |
2015 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Advanced lung cancers with epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19s) and EGFR exon 21 L858R point mutations (Ex21s) exhibit different clinical behavior.
|
26496308 |
2015 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The posterior fossa, the anatomic "watershed areas," and the gray-white matter junction were confirmed to be more commonly affected by lung cancer brain metastases, and brain metastases with epidermal growth factor receptor (EGFR) L858R mutation occurred more often in the caudate, cerebellum, and temporal lobe than those with exon 19 deletion of EGFR.
|
26519739 |
2016 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.
|
26689995 |
2016 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Targeted therapy for these lung cancers has been established based on evidence regarding mainly common mutations; that is, exon 19 deletions (Del19) and L858R.
|
27323238 |
2016 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma histology, with the intent of permitting use of these predictive biomarkers to select patients who will derive maximal benefit from approved oral tyrosine kinase inhibitors (TKIs) directed against EGFR and ALK, respectively.
|
27381270 |
2016 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
|
27433829 |
2016 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
|
27619632 |
2016 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer.
|
27643705 |
2016 |